Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level HER-2 expression: a case report

Overview of attention for article published in Frontiers in oncology, January 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 18,938 followers.

RT @FrontOncology: New research: Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with l…

27 Jan 2024

Reply Repost Favourite

RT @FrontOncology: New research: Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with l…

27 Jan 2024

Reply Repost Favourite

New research: Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level HER-2 expression: a case report: Large-cell neuroendocrine carcinoma (LCNEC) of the ovary is an extremely rare… https://t.co/Nh

27 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.